Drugs that contain Fluticasone Furoate
1. Arnuity Ellipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101866 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5873360 | GLAXOSMITHKLINE | Inhalation device |
Feb, 2016
(8 years ago) | |
| US7629335 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(3 years from now) | |
|
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(4 years from now) | |
|
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(4 years from now) | |
| US8201556 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2029
(4 years from now) | |
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
|
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(6 years from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(6 years from now) | |
|
US8746242 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-290) | Mar 01, 2026 |
| New Strength(NS) | May 17, 2021 |
| New Patient Population(NPP) | May 17, 2021 |
| New Product(NP) | Aug 20, 2017 |
Market Authorisation Date: 17 May, 2018
Treatment: Indicated for the once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 12 years of age and older
Dosage: POWDER;INHALATION
ARNUITY ELLIPTA family patents
2. Flonase Sensimist Allergy Relief patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101866 | GLAXOSMITHKLINE CONS | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6858596 | GLAXOSMITHKLINE CONS | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US7541350 | GLAXOSMITHKLINE CONS | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US9320862 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Nov, 2024
(6 months from now) | |
| US8062264 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Apr, 2026
(1 year, 11 months from now) | |
| US8752543 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Apr, 2026
(1 year, 11 months from now) | |
| US8347879 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Jul, 2028
(4 years from now) | |
| US8147461 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Oct, 2028
(4 years from now) | |
Market Authorisation Date: 27 April, 2007
Treatment: Otc use: allergy symptom reliever; Temporarily relieves these symptoms due to hay fever or other upper respiratory allergies; Nasal congestion, runny nose, sneezing, itchy nose, and (itchy water eyes ...
Dosage: SPRAY, METERED;NASAL
FLONASE SENSIMIST ALLERGY RELIEF family patents
3. Veramyst patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101866 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6858596 | GLAXOSMITHKLINE | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US7541350 | GLAXOSMITHKLINE | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US9320862 | GLAXOSMITHKLINE | Fluid dispensing device |
Nov, 2024
(6 months from now) | |
| US8752543 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2026
(1 year, 11 months from now) | |
| US8062264 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2026
(1 year, 11 months from now) | |
| US8347879 | GLAXOSMITHKLINE | Fluid dispensing device |
Jul, 2028
(4 years from now) | |
| US8147461 | GLAXOSMITHKLINE | Fluid dispensing device |
Oct, 2028
(4 years from now) | |
Market Authorisation Date: 27 April, 2007
Treatment: The treatment of the symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older; Treatment of rhinitis comprising the nasal application of a pharmaceutical formulation a...
Dosage: SPRAY, METERED;NASAL
VERAMYST family patents